Ionis Hosts 2022 Investor Day; Intercept Withdraws OCA MAA in NASH
A series of cardiometabolic-related news items have been observed: Ionis hosted its 2022 Investor Day (view slides), and Intercept announced it has withdrawn the obeticholic acid (OCA) Marketing Authorization Application for the treatment of fibrosis due to NASH. Below, FENIX provides highlights and insights from the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.